<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01258595</url>
  </required_header>
  <id_info>
    <org_study_id>FIM09</org_study_id>
    <secondary_id>UTN: U1111-1113-3648</secondary_id>
    <nct_id>NCT01258595</nct_id>
  </id_info>
  <brief_title>A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age</brief_title>
  <official_title>Safety and Immunogenicity of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to generate data on key parameters associated with assessment of
      influenza vaccines in individuals 50-64 years of age

      Primary Objective:

        -  To describe the immunogenicity of High-Dose Trivalent Inactivated Influenza Vaccine
           (TIV) compared to TIV.

        -  To describe the safety profile of High-Dose Trivalent Inactivated Influenza Vaccine, as
           assessed by solicited adverse reactions collected for 7 days post-vaccination, and
           unsolicited adverse events (including Serious Adverse Events and Adverse Events of
           Special Interests) collected between Visit 1 and Visit 2
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized to receive one dose of either High-Dose Trivalent Inactivated
      Influenza Vaccine or Trivalent Inactivated Influenza Vaccine. They will be followed up for
      safety for one month post-vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Vaccine Antibodies Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine.</measure>
    <time_frame>Day 0 and Day 28 post-vaccination</time_frame>
    <description>Serum antibody titers to vaccine antigens were assessed by means of the hemagglutination inhibition (HAI) assay method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Individual Titer Ratios (GMTRs) of Vaccine Antibodies Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine</measure>
    <time_frame>Day 0 and Day 28 Post-vaccination</time_frame>
    <description>Serum antibody titers to vaccine antigens were assessed by means of the hemagglutination inhibition (HAI) assay method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine</measure>
    <time_frame>Day 0 and Day 28 post-vaccination</time_frame>
    <description>Seroconversion: For participants with a Day 0 (pre-vaccination) titer &lt; 10 (1/dilution [1/dil]) a titer ≥ 40 (1/dil), and for participants with a Day 0 titer ≥ 10 (1/dil) a ≥ 4 fold increase of titer on Day 28.
Serum antibody titers were assessed by means of the hemagglutination inhibition (HAI) assay method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroprotection Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine</measure>
    <time_frame>Day 0 and Day 28 post vaccination</time_frame>
    <description>Seroprotection was defined as a titer ≥ 40 (1/dilution [1/dil]). Serum antibody titers were assessed by means of the hemagglutination inhibition (HAI) assay method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Injection Site or Systemic Reactions After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine</measure>
    <time_frame>Day 0 through Day 7 post-vaccination</time_frame>
    <description>Solicited Injection Site Reactions: Pain, Erythema, Swelling, Ecchymosis, and Induration. Solicited Systemic Reactions: Fever, Headache, Malaise, Myalgia, and Shivering</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>High-Dose Trivalent Inactivated Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trivalent Inactivated Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-Dose Trivalent Inactivated Influenza Vaccine</intervention_name>
    <description>0.5 mL Intramuscular</description>
    <arm_group_label>High-Dose Trivalent Inactivated Influenza Vaccine</arm_group_label>
    <other_name>Fluzone® High-Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent Inactivated Influenza Vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Trivalent Inactivated Influenza Vaccine</arm_group_label>
    <other_name>Fluzone®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 50 to 64 years (inclusive) on the day of vaccination

          -  Informed consent form has been signed and dated

          -  Medically stable

          -  Able to attend all scheduled visits and to comply with all trial procedures

          -  For a woman of childbearing potential, use of an effective method of contraception or
             abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after
             vaccination

        Exclusion Criteria:

          -  Known pregnancy, or a positive urine pregnancy test

          -  Currently breastfeeding a child

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or medical procedure in the 4 weeks preceding the trial vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Planned receipt of any vaccine in the 4 weeks following the trial vaccination (prior
             to the Visit 2 blood draw)

          -  Receipt of seasonal or pandemic influenza vaccine in the past 6 months

          -  Receipt of blood or blood-derived products in the past 3 months

          -  Systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine components,
             or a history of a life-threatening reaction to the standard-dose Trivalent Inactivated
             Influenza Vaccine or a vaccine containing any of the same substances

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within
             the preceding 6 months; or long-term systemic corticosteroid therapy

          -  Neoplastic disease or any hematologic malignancy

          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,
             contraindicating intramuscular vaccination

          -  Personal history of Guillain-Barré Syndrome

          -  Self-reported seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or
             Hepatitis C

          -  Deprived of freedom by an administrative or court order, or in an emergency setting,
             or hospitalized involuntarily

          -  Current alcohol abuse or drug addiction that might interfere with the ability to
             comply with trial procedures

          -  Identified as employees of the Investigator or study center, with direct involvement
             in the proposed study or other studies under the direction of that Investigator or
             study center, as well as family members (i.e., immediate, husband, wife and their
             children, adopted or natural) of the employees or the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ellicott City</city>
        <state>Maryland</state>
        <zip>21042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2010</study_first_submitted>
  <study_first_submitted_qc>December 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2010</study_first_posted>
  <results_first_submitted>September 19, 2011</results_first_submitted>
  <results_first_submitted_qc>September 19, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 27, 2011</results_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Trivalent Inactivated Influenza Vaccine</keyword>
  <keyword>High-Dose Trivalent Inactivated Influenza Vaccine</keyword>
  <keyword>Influenza vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 15 November to 10 December 2010 in 4 clinical centers in the US.</recruitment_details>
      <pre_assignment_details>A total of 300 participants who met the inclusion and exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fluzone® High-Dose Vaccine Group</title>
          <description>Participants who received a single dose of Fluzone® High-Dose vaccine, containing 60 µg hemagglutinin on Day 0</description>
        </group>
        <group group_id="P2">
          <title>Fluzone® Vaccine Group</title>
          <description>Participants who received a single dose of Fluzone® vaccine, containing 15 µg hemagglutinin on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluzone® High-Dose Vaccine Group</title>
          <description>Participants who received a single dose of Fluzone® High-Dose vaccine, containing 60 µg hemagglutinin on Day 0</description>
        </group>
        <group group_id="B2">
          <title>Fluzone® Vaccine Group</title>
          <description>Participants who received a single dose of Fluzone® vaccine, containing 15 µg hemagglutinin on Day 0</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
            <count group_id="B2" value="152"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="4.38"/>
                    <measurement group_id="B2" value="57.7" spread="4.14"/>
                    <measurement group_id="B3" value="57.7" spread="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Vaccine Antibodies Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine.</title>
        <description>Serum antibody titers to vaccine antigens were assessed by means of the hemagglutination inhibition (HAI) assay method.</description>
        <time_frame>Day 0 and Day 28 post-vaccination</time_frame>
        <population>Serum antibody titers to vaccine antigens were assessed in the full analysis set population.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone® High-Dose Vaccine Group</title>
            <description>Participants who received a single dose of Fluzone® High-Dose vaccine, containing 60 µg hemagglutinin on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Vaccine Group</title>
            <description>Participants who received a single dose of Fluzone® vaccine, containing 15 µg hemagglutinin on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Vaccine Antibodies Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine.</title>
          <description>Serum antibody titers to vaccine antigens were assessed by means of the hemagglutination inhibition (HAI) assay method.</description>
          <population>Serum antibody titers to vaccine antigens were assessed in the full analysis set population.</population>
          <units>1/dilution (1/dil)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: California - Pre-vaccination (N=147, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" lower_limit="30.0" upper_limit="54.5"/>
                    <measurement group_id="O2" value="28.8" lower_limit="21.8" upper_limit="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Victoria - Pre-vaccination (N=147, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="28.0" upper_limit="47.4"/>
                    <measurement group_id="O2" value="41.4" lower_limit="31.4" upper_limit="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Brisbane - Pre-vaccination (N=147, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="22.4" upper_limit="33.6"/>
                    <measurement group_id="O2" value="28.9" lower_limit="23.5" upper_limit="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: California - Post-vaccination (N=145, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1067" lower_limit="868" upper_limit="1312"/>
                    <measurement group_id="O2" value="745" lower_limit="585" upper_limit="948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Victoria - Post-vaccination (N = 145, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="936" lower_limit="745" upper_limit="1176"/>
                    <measurement group_id="O2" value="567" lower_limit="459" upper_limit="699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Brisbane - Post-vaccination (N=145, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203" lower_limit="171" upper_limit="241"/>
                    <measurement group_id="O2" value="127" lower_limit="104" upper_limit="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Individual Titer Ratios (GMTRs) of Vaccine Antibodies Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine</title>
        <description>Serum antibody titers to vaccine antigens were assessed by means of the hemagglutination inhibition (HAI) assay method.</description>
        <time_frame>Day 0 and Day 28 Post-vaccination</time_frame>
        <population>Serum antibody titers to vaccine antigens were assessed in the full analysis set population.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone® High-Dose Vaccine Group</title>
            <description>Participants who received a single dose of Fluzone® High-Dose vaccine, containing 60 µg hemagglutinin on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Vaccine Group</title>
            <description>Participants who received a single dose of Fluzone® vaccine, containing 15 µg hemagglutinin on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Individual Titer Ratios (GMTRs) of Vaccine Antibodies Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine</title>
          <description>Serum antibody titers to vaccine antigens were assessed by means of the hemagglutination inhibition (HAI) assay method.</description>
          <population>Serum antibody titers to vaccine antigens were assessed in the full analysis set population.</population>
          <units>1/dilution (1/dil)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: California</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" lower_limit="16.1" upper_limit="29.6"/>
                    <measurement group_id="O2" value="21.2" lower_limit="15.8" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="17.2" upper_limit="28.1"/>
                    <measurement group_id="O2" value="12.0" lower_limit="9.21" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.27" lower_limit="5.16" upper_limit="7.62"/>
                    <measurement group_id="O2" value="3.91" lower_limit="3.17" upper_limit="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine</title>
        <description>Seroconversion: For participants with a Day 0 (pre-vaccination) titer &lt; 10 (1/dilution [1/dil]) a titer ≥ 40 (1/dil), and for participants with a Day 0 titer ≥ 10 (1/dil) a ≥ 4 fold increase of titer on Day 28.
Serum antibody titers were assessed by means of the hemagglutination inhibition (HAI) assay method.</description>
        <time_frame>Day 0 and Day 28 post-vaccination</time_frame>
        <population>Seroconversion to the vaccine antigens was assessed in the full analysis set population.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone® High-Dose Vaccine Group</title>
            <description>Participants who received a single dose of Fluzone® High-Dose vaccine, containing 60 µg hemagglutinin on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Vaccine Group</title>
            <description>Participants who received a single dose of Fluzone® vaccine, containing 15 µg hemagglutinin on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine</title>
          <description>Seroconversion: For participants with a Day 0 (pre-vaccination) titer &lt; 10 (1/dilution [1/dil]) a titer ≥ 40 (1/dil), and for participants with a Day 0 titer ≥ 10 (1/dil) a ≥ 4 fold increase of titer on Day 28.
Serum antibody titers were assessed by means of the hemagglutination inhibition (HAI) assay method.</description>
          <population>Seroconversion to the vaccine antigens was assessed in the full analysis set population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: California</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroprotection Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine</title>
        <description>Seroprotection was defined as a titer ≥ 40 (1/dilution [1/dil]). Serum antibody titers were assessed by means of the hemagglutination inhibition (HAI) assay method.</description>
        <time_frame>Day 0 and Day 28 post vaccination</time_frame>
        <population>Seroprotection was assessed in the full analysis set population.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone® High-Dose Vaccine Group</title>
            <description>Participants who received a single dose of Fluzone® High-Dose vaccine, containing 60 µg hemagglutinin on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Vaccine Group</title>
            <description>Participants who received a single dose of Fluzone® vaccine, containing 15 µg hemagglutinin on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine</title>
          <description>Seroprotection was defined as a titer ≥ 40 (1/dilution [1/dil]). Serum antibody titers were assessed by means of the hemagglutination inhibition (HAI) assay method.</description>
          <population>Seroprotection was assessed in the full analysis set population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: California - Pre-vaccination (N=147, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Victoria - Pre-vaccination (N=147, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Brisbane - Pre-vaccination (N=147, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: California - Post-vaccination (N=145, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Victoria - Post-vaccination (N=145, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Brisbane - Post-vaccination (N=145, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Injection Site or Systemic Reactions After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine</title>
        <description>Solicited Injection Site Reactions: Pain, Erythema, Swelling, Ecchymosis, and Induration. Solicited Systemic Reactions: Fever, Headache, Malaise, Myalgia, and Shivering</description>
        <time_frame>Day 0 through Day 7 post-vaccination</time_frame>
        <population>Safety analysis was on all enrolled and vaccinated subjects with available reaction data, safety analysis set population.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone® High-Dose Vaccine Group</title>
            <description>Participants who received a single dose of Fluzone® High-Dose vaccine, containing 60 µg hemagglutinin on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Vaccine Group</title>
            <description>Participants who received a single dose of Fluzone® vaccine, containing 15 µg hemagglutinin on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Injection Site or Systemic Reactions After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine</title>
          <description>Solicited Injection Site Reactions: Pain, Erythema, Swelling, Ecchymosis, and Induration. Solicited Systemic Reactions: Fever, Headache, Malaise, Myalgia, and Shivering</description>
          <population>Safety analysis was on all enrolled and vaccinated subjects with available reaction data, safety analysis set population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Injection Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grad 3 Injection site Pain-Prevents daily activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Erythema (&gt;100 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Swelling (&gt;100 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Ecchymosis (&gt;100 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Induration (&gt;100 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (≥ 39.0 ºC or ≥ 102.1 ºF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Prevents daily activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Prevents daily activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Prevents daily activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering (Prevents daily activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination through 28 days post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fluzone® High-Dose Vaccine Group</title>
          <description>Participants who received a single dose of Fluzone® High-Dose vaccine, containing 60 µg hemagglutinin on Day 0</description>
        </group>
        <group group_id="E2">
          <title>Fluzone® Vaccine Group</title>
          <description>Participants who received a single dose of Fluzone® vaccine, containing 15 µg hemagglutinin on Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited Injection Site Pain</sub_title>
                <counts group_id="E1" events="112" subjects_affected="112" subjects_at_risk="148"/>
                <counts group_id="E2" events="85" subjects_affected="85" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Solicited Injection Site Erythema</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="147"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Solicited Injection Site Swelling</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="147"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Solicited Injection Site Induration</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="147"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Solicited Malaise</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="147"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Solicited Shivering</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="147"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited Myalgia</sub_title>
                <counts group_id="E1" events="70" subjects_affected="70" subjects_at_risk="147"/>
                <counts group_id="E2" events="46" subjects_affected="46" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited Headache</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="147"/>
                <counts group_id="E2" events="40" subjects_affected="40" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

